Efficacy and safety of hydromorphone or morphine for cancer pain using intrathecal drug delivery system:a meta-analysis
10.16781/j.CN31-2187/R.20230736
- VernacularTitle:氢吗啡酮或吗啡用于鞘内药物输注系统治疗癌痛的疗效及安全性的meta分析
- Author:
Rongrong LI
1
;
Hongbin YUAN
;
Yangyang WANG
;
Xingying HE
Author Information
1. 海军军医大学(第二军医大学)第二附属医院麻醉科,上海 200003
- Keywords:
cancer pain;
intrathecal drug delivery system;
morphine;
hydromorphone;
meta-analysis
- From:
Academic Journal of Naval Medical University
2024;45(8):990-998
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the efficacy and safety of hydromorphone or morphine for cancer pain using intrathecal drug infusion system(IDDS).Methods Chinese and English literature databases,including CNKI,Wanfang,VIP,CBM,PubMed,Cochrane Library,and Ovid,were searched from inception to Aug.31,2023 to collect randomized controlled trials(RCTs)about intrathecal infusion of morphine or hydromorphone in treatment of cancer pain.Two reviewers independently screened literature and extracted data according to the inclusion and exclusion criteria,and evaluated the quality of RCTs using a Cochrane bias risk assessment tool.Then,meta-analysis was performed using RevMan 5.4.1 software.Results A total of 6 RCTs,involving 544 patients,were enrolled.Among them,there were 282 cases in the hydromorphone group and 262 cases in the morphine group.The meta-analysis results showed that there were no significant differences in pain score or number of breakthrough pain episodes between the 2 groups after treatment(all P＞0.05).Compared with the morphine group,the incidence rates of nausea and vomiting,constipation,and somnolence were significantly decreased in the hydromorphone group(P≤0.05),and the quality of life was significantly higher(P＜0.05).Conclusion The efficacy of hydromorphone administered by IDDS for cancer pain is comparable to morphine;hydromorphone has advantages in reducing adverse reactions and improving quality of life of patients.
